OPK OPKO Health Inc.

OPKO Health to Participate in Two Upcoming Investor Conferences

OPKO Health to Participate in Two Upcoming Investor Conferences

MIAMI, May 15, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in two investor conferences over the coming weeks.

  • H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq, May 20 in New York City. Management will hold one-on-one meetings with investors and will participate in a fireside discussion at 9:00 a.m. Eastern time.
  • Jefferies Global Healthcare Conference, June 3-5 at the Marriott Marquis in New York City. Management will hold one-on-one meetings with investors on Wednesday, June 4th and will participate in a fireside discussion on Wednesday, June 4th at 11:05 a.m. Eastern time.

The fireside discussions at both conferences will be webcast live and available for replay in the Investors section of OPKO Health’s website and accessible by clicking .

About OPKO Health

OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit .

Contacts:

Alliance Advisors IR

Yvonne Briggs, 310-691-7100



or

Bruce Voss, 310-691-7100



EN
15/05/2025

Underlying

OPKOPKO Health Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OPKO Health Inc.

Jonathan Moreland
  • Jonathan Moreland
Free Trial
SHEN Shenandoah Tele...
PNFP Pinnacle Financ... ... (+15)

InsiderInsights.com Daily Ratings Report: August 8, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
PNFP PINNACLE FINANCIAL PARTNERS INC.
OPK OPKO HEALTH INC.
NPO ENPRO INDUSTRIES INC.
LLY ELI LILLY AND COMPANY
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
BRO BROWN & BROWN INC.
CRSP CRISPR THERAPEUTICS AG
OSPN ONESPAN
TROX TRONOX HOLDINGS PLC
MEC MAYVILLE ENGINEERING
PINE ALPINE INCOME PROPERTY TRUST
PTLO PORTILLOS INC
AUB ATLANTIC UNION BANKSHARES CORP
LNW LIGHT & WONDER INC.
22h / 52m 22h / 52m 1 EN
Free Trial
OPK OPKO Health In...

Opko Health Inc: 1 director

A director at Opko Health Inc bought 675,000 shares at 1.320USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

OPK OPKO HEALTH INC.
08/08/25 August 8, 2025 1 EN
 PRESS RELEASE
Free
OPK OPKO Health In...

OPKO Health Reports Second Quarter 2025 Business Highlights and Financ...

OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2025. Highlights from the second quarter of 2025 and recent weeks include the following: Merck advanced Phase 1 Epstein-Barr virus vaccine trial (). This investigational vaccine candidate is being developed in collaboration with Merck and evaluates safety and tolerability in up to 200 h...

July 31, 2025 1 EN
 PRESS RELEASE
Free
OPK OPKO Health In...

OPKO Health to Report Second Quarter 2025 Financial Results on July 31

OPKO Health to Report Second Quarter 2025 Financial Results on July 31 MIAMI, July 24, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2025 after the close of the U.S. financial markets on Thursday, July 31, 2025. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on July 31 beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-re...

July 24, 2025 1 EN
 PRESS RELEASE
Free
OPK OPKO Health In...

OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Ta...

OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress MIAMI and JERUSALEM, July 08, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (“OPKO”) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that their abstract “First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome” has been selected for a poster presentation at the 47th European Society for Clinical Nutrition & Metabolism (“ESPEN”) Congress, taking place September 13–16, 2025, in Prague, Czech Republic. A...

July 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch